KYV-101 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving KYV-101 Growth

1. Registrational and Regulatory Advancement in Key Autoimmune Indications

KYV-101 is progressing through registrational clinical programs with clear regulatory alignment with the US FDA:

Stiff Person Syndrome (SPS): Kyverna completed enrollment in the registrational KYSA-8 Phase II trial, designed with FDA alignment to support a Biologics License Application (BLA) submission in the first half of 2026.

Generalized Myasthenia Gravis (gMG): The KYSA-6 Phase II portion of a registrational Phase II/III study has reported positive interim data and is being expanded into a full registrational program, with Phase III enrollment expected to begin by the end of 2025.

2. Positive Clinical Data Showing Strong Potential Efficacy and Durability

Recent clinical and interim results show encouraging signals:

• In gMG, interim data from KYSA-6 showed 100% of patients demonstrated meaningful, rapid clinical improvements in key functional scores after a single KYV-101 infusion, even in patients resistant to previous immunosuppressive therapies.
• KYV-101 has shown durable disease control and improvements in multiple autoimmune settings in case reports and investigator-initiated trials, including improvements in mobility for SPS patients and sustained benefits in other treated individuals.

3. Significant Unmet Need and First-to-Market Opportunity in Rare Autoimmune Diseases

Stiff Person Syndrome (SPS) currently has no FDA-approved treatments, making KYV-101's potential approval highly notable as a first-in-class therapy.

In myasthenia gravis, treatment options remain limited with many patients needing chronic immunosuppression despite suboptimal responses; a single-dose CAR T therapy could disrupt standard of care if validated.

4. Broad Potential Across Multiple Autoimmune and Neuroinflammatory Diseases

Beyond SPS and gMG, KYV-101 is being evaluated in additional autoimmune diseases:

Ongoing Phase I/II trials in lupus nephritis (KYSA-1 and KYSA-3).

Investigator-initiated and company trials exploring signals in multiple sclerosis, rheumatoid arthritis, and systemic sclerosis.

Presentation of case data suggesting activity in multiple disease states enriches the strategic opportunity for KYV-101.

5. Strategic Corporate Positioning and Pre-Launch Preparedness

Kyverna has taken steps to support late-stage development and eventual commercialization:

Alignment with the FDA on registrational pathways and trial designs for multiple indications.

Investment in manufacturing capabilities with multiple partners to support commercial-scale production.

Ongoing strategic outreach (e.g., virtual KOL events) to educate physicians on CAR T potential in autoimmune diseases.

KYV-101 Recent Developments

• In December 2025, Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced positive topline data from KYSA-8, its registrational Phase II trial of mivocabtagene autoleucel ('miv-cel', formerly KYV-101), a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation, in stiff person syndrome (SPS).
• In October 2025, Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the presentation of data from the Phase I portion of an investigator-initiated Phase I/II trial (IIT) evaluating KYV-101 in patients with active and treatment-refractory rheumatoid arthritis (RA).

"KYV-101 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of KYV-101 for potential indication like Myasthenia gravis, Multiple sclerosis, Stiff-person syndrome, Lupus nephritis, Rheumatoid arthritis, and Systemic scleroderma in the 7MM. A detailed picture of KYV-101's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the KYV-101 for potential indications. The KYV-101 market report provides insights about KYV-101's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current KYV-101 performance, future market assessments inclusive of the KYV-101 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of KYV-101 sales forecasts, along with factors driving its market.

KYV-101 Drug Summary

KYV-101 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Kyverna Therapeutics, utilizing a fully human anti-CD19 CAR construct previously validated in B-cell lymphoma patients for its improved safety profile with lower cytokine release. The therapy involves leukapheresis to collect patient T-cells, ex vivo genetic modification to express the CD19-targeting CAR, expansion, and reinfusion at a dose of 1X10^8 CAR+ T cells following lymphodepleting chemotherapy (e.g., fludarabine/cyclophosphamide), enabling deep and durable depletion of CD19+ B-cells-including autoreactive pathogenic B-cells in circulation and tissues-to reset aberrant immune responses in autoimmune diseases. It has demonstrated robust clinical efficacy in early trials, such as the KYSA-6 Phase II/III study in generalized myasthenia gravis (gMG), achieving rapid, sustained reductions in MG-ADL (-8.0 points) and QMG (-7.7 points) scores at 24 weeks across all patients regardless of prior biologics exposure, alongside positive effects on regulatory T-cells; additional programs target progressive multiple sclerosis (excellent Phase 1 safety with CNS penetration and immunomodulation) and systemic sclerosis. KYV-101 exhibits a manageable safety profile, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported, and primarily low-grade adverse events. The report provides KYV-101's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the KYV-101 Market Report

The report provides insights into:

• A comprehensive product overview including the KYV-101 MoA, description, dosage and administration, research and development activities in potential indication like Myasthenia gravis, Multiple sclerosis, Stiff-person syndrome, Lupus nephritis, Rheumatoid arthritis, and Systemic scleroderma.
• Elaborated details on KYV-101 regulatory milestones and other development activities have been provided in KYV-101 market report.
• The report also highlights KYV-101's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The KYV-101 market report also covers the patents information, generic entry and impact on cost cut.
• The KYV-101 market report contains current and forecasted KYV-101 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The KYV-101 market report also features the SWOT analysis with analyst views for KYV-101 in potential indications.

Methodology:

The KYV-101 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KYV-101 Analytical Perspective by DelveInsight

• In-depth KYV-101 Market Assessment

This KYV-101 sales market forecast report provides a detailed market assessment of KYV-101 for potential indication like Myasthenia gravis, Multiple sclerosis, Stiff-person syndrome, Lupus nephritis, Rheumatoid arthritis, and Systemic scleroderma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted KYV-101 sales data uptil 2034.

• KYV-101 Clinical Assessment

The KYV-101 market report provides the clinical trials information of KYV-101 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

KYV-101 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

KYV-101 Market Potential & Revenue Forecast

• Projected market size for the KYV-101 and its key indications
• Estimated KYV-101 sales potential (KYV-101 peak sales forecasts)
• KYV-101 Pricing strategies and reimbursement landscape

KYV-101 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• KYV-101 Market positioning compared to existing treatments
• KYV-101 Strengths & weaknesses relative to competitors

KYV-101 Regulatory & Commercial Milestones

• KYV-101 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

KYV-101 Clinical Differentiation

• KYV-101 Efficacy & safety advantages over existing drugs
• KYV-101 Unique selling points

KYV-101 Market Report Highlights

• In the coming years, the KYV-101 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The KYV-101 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KYV-101's dominance.
• Other emerging products for Myasthenia gravis, Multiple sclerosis, Stiff-person syndrome, Lupus nephritis, Rheumatoid arthritis, and Systemic scleroderma are expected to give tough market competition to KYV-101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KYV-101 in potential indications.
• Analyse KYV-101 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted KYV-101 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of KYV-101 in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of KYV-101? How strong is KYV-101's clinical and commercial performance?
• What is KYV-101's clinical trial status in each individual indications such as Myasthenia gravis, Multiple sclerosis, Stiff-person syndrome, Lupus nephritis, Rheumatoid arthritis, and Systemic scleroderma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KYV-101 Manufacturers?
• What are the key designations that have been granted to KYV-101 for potential indications? How are they going to impact KYV-101's penetration in various geographies?
• What is the current and forecasted KYV-101 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of KYV-101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to KYV-101 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is KYV-101? What is the duration of therapy and what are the geographical variations in cost per patient?